Financial Results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Shelter Pharma Limited reported audited standalone results for FY25 (year ended March 31, 2025). Revenue from operations grew 26.6% YoY to ₹5,066.02 lakhs (vs ₹4,002.29 lakhs in FY24). Profit after tax rose about 16.7% to ₹723.74 lakhs (vs ₹620.02 lakhs), translating to an EPS of ₹6.26 (vs ₹5.36). Operating profit before tax came in at ₹967.70 lakhs versus ₹828.26 lakhs last year. A notable positive is the swing in operating cash flow, which turned positive at ₹548.22 lakhs in FY25 compared to a negative ₹196.17 lakhs in FY24. Statutory auditor M/s Mendajiwala & Co. issued an unmodified opinion. The Board also appointed a new internal auditor (M/s I I Lakhani & Co.) for FY26 and reappointed the secretarial auditor for a five-year term (FY26–FY30).
Strong top-line growth above 20% is positive for shareholders, but profitability (PAT) growth lagged revenue and EBITDA margins appear to have compressed, suggesting rising input or operating costs. The turnaround to positive operating cash flow is a healthy sign for near-term liquidity.